4 Reasons Telemedicine Will Trend Upward in 2015
Why? Well for a number of reasons. But here are the four most promine...
Telemedicine may be one of the biggest digital health trends we will see in 2015.
Why? Well for a number of reasons. But here are the four most prominent.
1. Faster internet connections and better software will provide a better video chat experience than before.
2. With mobile devices, patients can consult a doctor from anywhere.
3. The adoption of electronic health records makes it easier for doctors to access patient records.
4. Patients are comfortable with asynchronous messaging, which can be more time-efficient for doctors.
From the provider’s perspective, telemedicine has the potential to save money and make better use of time. And from a patient’s perspective, telemedicine means shorter wait times and ease of access.
While the youth would seem most likely to use technology for health care, telemedicine could also have a major impact on the older generation as they are more likely to have difficulty traveling to see a doctor in person.
In the last few years, more and more patients have increasingly looked to retail pharmacies in their neighborhoods for routine health care services because it’s more convenient than visiting their doctor. The logical next step is that they won’t have to leave their homes at all. This is where telemedicine comes in.
Thanks to startups like Doctors on Demand, Medicast and Twine Health, consumers are already being allowed direct access to doctors through their smartphones. In the future, providers may partner with platforms such as these to connect their doctors with patients.
Additionally, these apps could be offered through employers or insurance companies to help reduce costs or improve the quality of care.
Telemedicine has the capability to not only become an investment opportunity, but a trend that can improve the doctor-patient relationship as well.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.